Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy is ending. Now the Danish drugmaker is ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.